Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients

The development of novel antiviral agents and immunomodulatory approaches to cure hepatitis B virus (HBV) infection requires new biomarkers capable of reflecting the intrahepatic activity of the virus and chronic HBV (CHB) stages and defining new meaningful treatment endpoints. Indeed, there is an unmet need for standardized assays able to provide mechanistic insights into the effects of the novel antiviral and immunomodulatory agents and to assess treatment efficacy.1

Source: Journal of Hepatology - December 7, 2018 Category: Gastroenterology Authors: Barbara Testoni, Fanny Leboss é, Caroline Scholtes, Françoise Berby, Clothilde Miaglia, Miroslava Subic, Alessandro Loglio, Floriana Facchetti, Pietro Lampertico, Massimo Levrero, Fabien Zoulim Tags: Research Article Source Type: research